ATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A∗0201.
Yuan L, Li S, Zhu Y, Yang L, Zhang X, Qu Y, Wang Z, Duan J, Zhong J, Tian Y, Liu L, Sun B, Fei K, Liu Z, Zhang J, He Y, Guo Y, He D, Zhuang W, Zhang J, Ma Z, Bai H, Wang J.
Yuan L, et al. Among authors: qu y.
EBioMedicine. 2025 Jan 13;112:105515. doi: 10.1016/j.ebiom.2024.105515. Online ahead of print.
EBioMedicine. 2025.
PMID: 39808946